News | April 29, 2023
RPG Life Sciences posts Q4 revenue at Rs 118.49 Cr
Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23
Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
The company will submit its comprehensive response on these observations to the US FDA within the stipulated time
The company has posted net profit of Rs.464.4 crores for the Financial Year ended March 31, 2023
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
Bridging the gap between histopathology and molecular pathology
New high-tech facility in Biberach offers attractive workplaces for more than 500 scientists
Subscribe To Our Newsletter & Stay Updated
